甘李药业(603087.SH)：获得《药物临床试验批准通知书》

Group 1 - Company Gannee Pharmaceutical (甘李药业) announced that its wholly-owned subsidiary received the clinical trial approval for the investigational drug GLR1044 injection from the National Medical Products Administration [1] - GLR1044 injection is a biosimilar to Dupilumab (达必妥®) and is indicated for the treatment of moderate to severe atopic dermatitis in adults who have inadequate control with topical prescription medications [1] - The drug can be used alone or in combination with topical corticosteroids [1] Group 2 - Atopic Dermatitis (AD) is a common chronic inflammatory skin disease affecting approximately 204 million people globally, with an adult prevalence rate of about 10.6% in China [2] - The incidence of AD has been increasing annually, with nearly 30% of patients classified as moderate to severe, totaling over 67 million individuals in 2020 [2] - The number of moderate to severe AD patients in China is expected to exceed 75 million by 2025, with the disease potentially lasting for decades in adults [2]